PE0139 is a novel, super-long-acting basal insulin for the treatment of hyperglycemia associated with diabetes dosed as a once-weekly injection. PE0139 is a fully mature, native insulin molecule (B and A chains) genetically fused to our ELP biopolymer. The compound is manufactured using our ELP-based E. coli expression system, where refolding of the drug occurs naturally in the cytosol. PE0139 is in a simple formulation that facilitates co-formulation with GLP-1 receptor agonists, including our proprietary GLP-1, PB1023, and other GLP-1 receptor agonists.

A Phase 1 single ascending dose study of PE0139 in adults with type 2 diabetes demonstrated prolonged exposure to the drug that would enable once-weekly administration and a low peak-to-trough ratio, which is particularly important for basal insulin. This profile was confirmed in a Phase 2a multiple ascending dose trial.

PhaseBio is no longer pursuing PE0139 due to changes in the competitive environment for the treatment of type 2 diabetes.